SG Americas Securities
LENZ icon

SG Americas Securities’s LENZ Therapeutics LENZ Stock Holding History

SG Americas Securities’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,458
Closed -$158K – 3813
2024
Q4 		$158K Buy
5,458
+935
+21% +$28.5K ﹤0.01% 2372
2024
Q3 		$107K Buy
+4,523
New +$100K ﹤0.01% 3016
2024
Q1 		– Sell
-2,190
Closed -$40K – 3519
2023
Q4 		$40K Buy
2,190
+430
+24% +$7.1K ﹤0.01% 2955
2023
Q3 		$31K Buy
+1,760
New +$30.6K ﹤0.01% 3012
2021
Q4 		– Sell
-1,035
Closed -$119K – 3867
2021
Q3 		$119K Buy
+1,035
New +$153K ﹤0.01% 3584

Other funds holding LENZ

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Alpha Wave Global
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SG Americas Securities's LENZ Position: Q1 2025 in Review

SG Americas Securities sold out of LENZ Therapeutics (LENZ) in Q1 2025, closing a stake of 5,458 shares — an estimated $158K sold.

SG Americas Securities first reported a position in LENZ in Q3 2021 and held it in 5 quarters. The position peaked at $158K in Q4 2024. 105 funds tracked by Wall St. Rank hold LENZ as of Q1 2025.

  • SG Americas Securities reported no remaining LENZ Therapeutics position as of Q1 2025 after selling out during the quarter.
  • SG Americas Securities sold 5,458 LENZ Therapeutics shares in Q1 2025, an estimated $158K.
  • SG Americas Securities first reported a position in LENZ Therapeutics in Q3 2021 and held it in 5 quarters.
  • SG Americas Securities's LENZ Therapeutics position peaked at $158K in Q4 2024.
  • 105 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2025.

Based on SG Americas Securities's 13F filing for Q1 2025, filed 15 Apr 2025.